NASDAQ · SLS
Healthcare · Biotechnology
$11.65
Up+$0.39 (+3.46%)
Updated Oct 10, 2026, 4:24 PM
SID Score
4.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · SLS
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 9, 2026
SLS closed at $11.65 after 21 trading sessions, up 0.91% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 9, 2026 | $11.38 | $11.805 | $11.26 | $11.65 | 4.18M |
| Oct 8, 2026 | $11.17 | $11.34 | $10.71 | $11.26 | 4.21M |
| Oct 7, 2026 | $11.28 | $11.54 | $11.1451 | $11.31 | 3.14M |
| Oct 6, 2026 | $11.63 | $11.6712 | $11.111 | $11.34 | 3.98M |
| Oct 5, 2026 | $11.77 | $11.77 | $11.35 | $11.63 | 4.51M |
| Oct 2, 2026 | $11.50 | $12.00 | $11.38 | $11.74 | 3.85M |
| Oct 1, 2026 | $12.15 | $12.25 | $11.20 | $11.33 | 6.23M |
| Sep 30, 2026 | $11.51 | $12.53 | $11.20 | $12.31 | 8.62M |
| Sep 29, 2026 | $11.50 | $11.64 | $11.37 | $11.51 | 3.27M |
| Sep 28, 2026 | $11.51 | $11.8493 | $11.31 | $11.59 | 3.76M |
| Sep 25, 2026 | $11.99 | $12.15 | $11.50 | $11.61 | 4.45M |
| Sep 24, 2026 | $11.43 | $12.04 | $11.10 | $11.98 | 4.65M |
| Sep 23, 2026 | $11.92 | $12.1399 | $11.42 | $11.52 | 3.89M |
| Sep 22, 2026 | $11.41 | $12.0699 | $11.17 | $12.02 | 5.97M |
| Sep 21, 2026 | $11.59 | $11.94 | $11.13 | $11.37 | 5.64M |
| Sep 18, 2026 | $11.60 | $11.78 | $11.06 | $11.49 | 14.61M |
| Sep 17, 2026 | $11.305 | $11.80 | $11.2338 | $11.53 | 4.81M |
| Sep 16, 2026 | $11.24 | $11.735 | $11.24 | $11.66 | 5.13M |
| Sep 15, 2026 | $11.60 | $11.70 | $11.03 | $11.29 | 5.24M |
| Sep 14, 2026 | $10.91 | $12.28 | $10.784 | $11.725 | 10.54M |
| Sep 11, 2026 | $13.55 | $13.74 | $11.38 | $11.545 | 14.71M |
The latest Smart Investors Daily articles mentioning SLS.
Company
Market Activity
Research & News
SLS research
Company profile and research snapshot.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 16, 2025 | Maxim Group | Buy | — |
| Nov 22, 2023 | Cantor Fitzgerald | Overweight | — |
| Sep 7, 2023 | Cantor Fitzgerald | Overweight | — |
| Nov 15, 2022 | Alliance Global Partners | Buy | — |
| Jun 28, 2022 | Cantor Fitzgerald | Overweight | — |
No generated briefing is available yet.
Yahoo · Oct 8, 2026
A new study of 2,610 AML patients found a median survival of 11.4 months with Venetoclax-based therapy versus 8.2 months with hypomethylating drugs alone.
Yahoo · Oct 2, 2026
Moderna will replace Warner Bros. Discovery in the Nasdaq-100 before markets open on Oct.9.
Yahoo · Oct 1, 2026
Retail investors speculated that Sellas’ office lease through September 2027 provides stability for clinical results and potential deal discussions.
Yahoo · Oct 1, 2026
Shares of Sellas Life Sciences Group Inc. (NASDAQ:SLS) nosedived by 16.6 percent in the third quarter of the year—from $14.76 on June 30 to $12.31 on Wednesday—as sentiment was dragged down by the delays and uncertainties surrounding the clinical results of its treatment candidate for acute myeloid leukemia (AML). In Wednesday’s trading alone, the stock […]
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning SLS.
